APAtmaram Pandurang Pawar

Atmaram Pandurang Pawar

*This is an algorithmically generated author record based on publicly available information.

Atmaram Pandurang Pawar has a total of 49 co-authors. Here are the top co-authors by number of shared publications:

  • C. Bothiraja

    Department of Pharmaceutics, Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to be University), Pune 411038

    6 shared publications
  • Praveen Sher

    B's Research Group-Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence of Tissue Engineering and Regenerative Medicine, AvePark, Zona Industrial da Gandra, S. Cláudio do Barco, 4806-909 Caldas das Taipas-Guimarães, Portugal. ICVS/3B's, PT Government Associated Laboratory, Braga/Guimarães, Portugal

    5 shared publications
  • Shivajirao Kadam

    Bharati Vidyapeeth Bhavan, Bharati Vidyapeeth University, Pune 411030, India

    5 shared publications
  • Piyush Pradeep Mehta

    Global Respiratory R&D, Cipla R&D Center

    4 shared publications
  • Bothiraja Chellampillai

    Department of Pharmaceutics, Poona College of Pharmacy, Bharati Vidyapeeth University, Pune, Maharashtra, India

    3 shared publications
  • Kakasaheb Mahadik

    Department of Pharmaceutical Chemistry, Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to be University), Pune 411038, Maharashtra, India

    3 shared publications

Latest Publications

  • Effect of Physicochemical and Rheological Properties of Ibuprofen Loaded Ethosomal Gel and its Optimization by 32 Factorial Design

    by Beeravelli Sudhakar, Atmaram P Pawar, Nimmathota Madhavi

    The current research work aimed to develop and evaluate the ibuprofen loaded ethosomal gel for transdermal delivery. Ibuprofen is an anti-inflammatory drug. On oral administration, it undergoes extensive hepatic metabolism. It has short biological half-life (1.8-2hr) and low bioavailability (49-70%). To overcome the side effects, it would be preferable to apply via transdermal delivery. Ibuprofen loaded ethosomes were prepared by film hydration technique using 32 factorial design and characterized for various physicochemical parameters. The optimized ethosomes was incorporated into gel using carbopol 940NF as a gel base. The developed gels were tested against rheology, ex vivo skin permeation studies, FTIR studies and stability studies. The prepared ethosomal dispersion shown particle size in the range of 140 nm to 242nm, zeta potential was found in the range of -18 to -36mV, %EE was found in the range of 44 to 84% and in vitro permeation studies were found in the range of 71 to 94% respectively. Based on rheological properties, 1%w/v concentration was optimized among the prepared gels. The ethosomal gel flux was found to be 27µg/cm2/hr which was found as better than other test products. FTIR studies revealed that there was no incompatibity between drug and excipients. Stability studies resulted that the optimum storage condition (2-8°C) doesn’t effect on degradation of physicochemical properties. It was concluded that ethosomes alters physicochemical properties of drug and thus enhances its permeation across the skin. Hence, ethosomes are considered as promising tool for anti-inflammatory therapy via transdermal delivery. Key words: Factorial design, Gel, Rheology, Permeation, Ethosomes

  • Investigation of novel sorafenib tosylate loaded biomaterial based nano-cochleates dispersion system for treatment of hepatocellular carcinoma

    by Raj J. Ahiwale, Bothiraja Chellampillai, Atmaram P. Pawar

    Sorafenib tosylate (ST), a European Medicines Agency (EMEA) and the U.S. Food and Drug Administration (FDA) approved orally active anticancer drug for liver cancer therapy. However, ST shows low oral bioavailability and therapeutic efficacy due to poor solubility, first-pass metabolism and narrow therapeutic window. Nano-cochleates are lipid constructed supramolecular congregations constituted of a negatively charged phospholipid with a divalent cation having potential targeting efficiency to cancer cells. In the present, we investigated the ST loaded nano-cochleates (STNCs) compressing 1,2-dioleoyl-sn-glycero-3-phospho-L-serine sodium salt (DOPS-Na) and cholesterol to increase ST oral bioavailability and therapeutic efficacy with low toxicity. The optimized STNCs showed entrapment efficiency, particle size and zeta potential of 85.55 ± 2.46%, 470 ± 23 nm, and −44.5 ± 6.58 mV, respectively. The STNCs demonstrated 2.18 fold improvement in oral bioavailability with 3.21 and 2.29 fold decrease in half-life and mean residence time as well as 2.12 fold enhancement in-vitro cell viability as compared to ST alone. STNCs reversed the tumor formation in diethylnitrosamine (DEN)-induced rat hepatocellular carcinoma (HCC) which was reflected in the histopathological study. Further, antioxidant parameters, liver function tests, and hematological analysis revealed that STNCs had a pronounced effect on liver cancer. The nano-cochleates can stand out as a technology to facilitate the administration of ST in the clinical setting. Graphical Abstract


  • Investigation of 1,2-Dimyristoyl-sn-Glycero-3-Phosphoglycerol-Sodium (DMPG-Na) Lipid with Various Metal Cations in Nanocochleate Preformulation: Application for Andrographolide Oral Delivery in Cancer Therapy

    by Raj J. Ahiwale, Bothiraja Chellampillai, Atmaram P. Pawar

    This study aimed at carrying out a preformulation investigation of nanocochleates (NCs) and develop andrographolide-loaded nanocochleates. Preformulation s


  • Open Access

    HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY FOR THE SIMULTANEOUS ESTIMATION OF CEFOPERAZONE AND SULBACTAM IN RAT PLASMA AND ITS IMPORTANCE IN THERAPEUTIC DRUG MONITORING

    by Swati Korake, Abhishek Pawar, Sushank Surywanshi, C. Bothiraja, Atmaram Pawar

    Objective: To study the Therapeutic drug monitoring and pharmacokinetics of marketed antibiotics formulation by developing a sensitive and specific Bioanalytical Chromatographic method. Methods: In the present study, we developed a rapid, sensitive and selective chromatographic method for simultaneous estimation of Cefoperazone (CEF) And Sulbactam (SAL) in male Wistar rat plasma. A novel liquid phase extraction method has adopted the preparation of plasma sample preparation. The CEF and SAL were eluted on a peerless Basic C18 (25 cm; 4.6 mm x 5 µm) column maintained at controlled environmental conditions. The gradient mobile phase comprised of 10 mmol ammonium acetate and acetonitrile. A UV detector was set at 250 nm and retention times for CEF and SAL were approximately 5.6 and 14.2 min, respectively. The proposed HPLC method was validated according to the US FDA guidelines with respect to the linearity, accuracy, precision, detection and quantitation limits, robustness and specificity. Results: Calibration curves of CEF and SAL were linear across the concentration range of 600-1000 and 6-10 µg/ml, with correlation coefficients (r2)>0.9977 and (r2)>0.9987, respectively. The limits of detection for CEF and SAL were 70.48 and 0.35 µg/ml, respectively. Additionally, CEF and SAL were stable in plasma for at least 24 h when stored at room temperature and 2-8 °C. Conclusion: The developed chromatographic method was effectively utilized to measure the plasma CEF and SAL concentrations in a pharmacokinetics study after intravenous injection to the healthy male Wistar rats.


  • Open Access

    Advanced development of a non-ionic surfactant and cholesterol material based niosomal gel formulation for the topical delivery of anti-acne drugs

    by Akhilesh Shah, Sanjay . Boldhane, Atmaram P Pawar, Chellampillai Bothiraja

    The aim of the present investigation was to develop adapalene (ADP), a high lipophilicity and low solubility anti-acne drug-loaded niosomal topical gel formulation, in order to improve its therapeutic efficacy.


  • Probing the influence of lactose fines, a USP modified induction port and modified DDU apparatus on the aerodynamic behavior of a fluticasone propionate dry powder inhaler

    by Piyush Mehta, C. Bothiraja, Shivajirao Kadam, Atmaram Pawar

    The objective of the present study is to understand the effects of lactose fines, a USP modified induction port (IP) and USP modified glass sampling apparatus (DDU apparatus) on the aerodynamic behavior of a fluticasone propionate (FP) dry powder inhaler (DPI). Lactose carriers containing 0 to 25% lactose fines were assessed for various physicochemical properties. Also, formulated FP DPIs were analyzed in terms of aerodynamic behavior using a multistage cascade assembly and DDU apparatus equipped with Revolizer® at a flow rate of 60 L min−1. The physicochemical characterization of lactose carriers showed that there were remarkable differences in particle size distribution, surface area and surface roughness. The formulated FP DPIs exhibited acceptable percentage content uniformity (>96%). A cascade impactor equipped with the USP modified IP showed significant differences in recovered and emitted doses compared to the USP IP. Additionally, in comparison to the USP IP, the USP modified IP showed a lower amount of drug deposition within the IP, irrespective of the lactose fines concentration. Besides, a formulated FP DPI showed a higher (>95%) mean delivered dose using the modified DDU apparatus at a flow rate of 60 L min−1. Briefly, not only the formulation properties and inhalation device but also the IP geometry had significant impacts on the in vitro analysis. The present investigation is the first detailed account of FP aerosolization performance using USP modified IP and DDU apparatus. Therefore, these findings may be of high importance for both academics and industrial researchers.


  • Effect of USP Induction Ports, Glass Sampling Apparatus, and Inhaler Device Resistance on Aerodynamic Patterns of Fluticasone Propionate–Loaded Engineered Mannitol Microparticles

    by Piyush Mehta, C. Bothiraja, Shivajirao Kadam, Atmaram Pawar

    The present investigation is to study the effect of two different induction ports (IP), i.e., USP IP and USP-modified IP equipped with andersen cascade impactor on in vitro aerodynamic performance along with the impact of USP-modified glass sampling apparatus on delivered dose uniformity of fluticasone propionate (FP) dry powder inhaler (DPI). FP DPI was fabricated by spray drying technique using engineered mannitol microparticles (EMP) with different force controlling agents, i.e., leucine and magnesium stearate. Additionally, commercially available two DPI inhaler devices namely Handihaler® and Breezhaler® were used to aerosolize the FP blends. Spherical smooth surface of EMP showed good powder flow properties and acceptable percentage content uniformity (> 95%). Amounts of FP deposited in cascade assembly using USP-modified IP with the Breezhaler® device was significantly higher (1.32-fold) as compared with the Handihaler® device. Moreover, USP-modified IP showed better deposition as compared with USP IP. Additionally, both inhaler devices showed a satisfactory delivered dose (> 105%) for FP using modified glass sampling apparatus at a flow rate of 60 L/min for 2 s. It was interesting to note that not only formulation properties but also IP geometry and device resistance have significant impact on DPI deposition pattern. This study is a first detailed account of aerodynamic performance of FP using USP-modified IP and USP-modified glass sampling apparatus. Thus, it can be of potential importance for both the academic and industry perspective.


  • Open Access

    Phytoconstituent based dry powder inhalers as biomedicine for the management of pulmonary diseases

    by Piyush Mehta, C. Bothiraja, Kakasaheb Mahadik, Shivajirao Kadam, Atmaram Pawar


  • Potential of dry powder inhalers for tuberculosis therapy: facts, fidelity and future

    by Piyush Mehta, C. Bothiraja, Shivajirao Kadam, Atmaram Pawar

    Tuberculosis (TB) is a contagious and airborne infectious disease caused by the pathogen Mycobacterium tuberculosis (Mtb). In spite of substantial research efforts, continuous multiple high-dose drug therapy regularly for 4–7 months can impede patient quality of life. The pathology of TB and biology of pulmonary airways permits for a variety of drug delivery strategies and natural route of infection denotes a more logical remedial approach for treatment of TB. Pulmonary delivery is non-invasive, allow easy transcytosis in alveolar region, avoids first-pass metabolism and extensive vascularization facilitates delivery of therapeutic agents to infection site. It also potentially reduces the frequency with dose requirement and linked side effects. Dry powder is a most preferred inhalation option due to their greater physiochemical stability over liquid or suspension based formulations. Dry powder inhalers (DPIs) are easy to handle and appropriate for high-dose formulations. Moreover, the progress of disciplines such as nanotechnology, particle engineering, material science and molecular biology permits further expansion of treatment capability and efficiency. Thus, this article will focus on the role of novel DPIs systems for treatment of TB. This article also contains a dedicated section discussing about technical limitations and clinical challenges with help of strengths, weaknesses, opportunities and threats (SWOT) analysis. Additionally, it will also offer some basic background information for drug repurposing, formulation development and drug delivery systems.


  • Evaluation of Serum Methotrexate Level by Using Chemiluminescent Microparticle Immuno Assay (CMIA)

    by Manjusha Sajith, Atmaram Pawar, Neela Vaidya, Kannan Subramanian, Vibha Sanjay Bafna, Sandip Bartakke

    Methotrexate (MTX) plays important treatment modalities for several paediatric cancers. Several automated binding assays and chromatographic methods was developed for estimating Methotrexate levels in serum and these methods are time consuming & utility of these methods in hospital set up is minimum. The ARCHITECT Methotrexate Assay by Chemiluminescent Microparticle Immuno Assay (CMIA) technology offers a sensitive & rapid estimation of Methotrexate in serum samples. So aim of this study is to evaluate the performance of ARCHITECT Methotrexate Assay kit in Chemiluminescent Microparticle Immuno Assay (CMIA) technology and to determine the level of serum methotrexate after 48 hours of Methotrexate infusion. ARCHITECT Methotrexate Assay kit was validated as per U.S Food and Drug Administration (USFDA) Bio analytical guidelines. The linearity was found to be in the range of 0.02–1.49 μmol/L with R2 0.99. The ARCHITECT Methotrexate assay showed a maximal Limit Of Detection of 0.0060 μmol/L. The Limit of quantification was found to be 0.04 μmol/L. Recovery of the sample was found to be 98.9 %. The intraday precision study showed a C.V. of 4.48 % at the lowest level and 3.83 % at the highest level where as interday precision study showed a C.V. of 2.14 % at the lowest level and 2.89 % at the highest level. The mean concentration of serum MTX after 48 hours of High Dose Methotrexate Infusion was found to be 0.487±0.357 μMol/L. The ARCHITECT assay is suitable for monitoring serum Methotrexate and showed satisfactory performance in the analysis of low concentrated samples.